Form 8-K - Current report:
SEC Accession No. 0001437749-25-008777
Filing Date
2025-03-21
Accepted
2025-03-21 17:21:28
Documents
31
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250319_8k.htm   iXBRL 8-K 29655
2 EXHIBIT 99.1 ex_792256.htm EX-99.1 42811
3 EXHIBIT 99.2 ex_792257.htm EX-99.2 8121
8 a01.jpg GRAPHIC 76320
9 a02.jpg GRAPHIC 209888
10 a03.jpg GRAPHIC 352061
11 a04.jpg GRAPHIC 395602
12 a05.jpg GRAPHIC 404317
13 a06.jpg GRAPHIC 360248
14 a07.jpg GRAPHIC 328222
15 a08.jpg GRAPHIC 268068
16 a09.jpg GRAPHIC 349755
17 a10.jpg GRAPHIC 270551
18 a11.jpg GRAPHIC 238766
19 a12.jpg GRAPHIC 200747
20 a13.jpg GRAPHIC 208229
21 logo01.jpg GRAPHIC 3904
22 logo02.jpg GRAPHIC 9588
  Complete submission text file 0001437749-25-008777.txt   5309964

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250317.xsd EX-101.SCH 4041
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250317_def.xml EX-101.DEF 13413
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250317_lab.xml EX-101.LAB 17610
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250317_pre.xml EX-101.PRE 13390
33 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250319_8k_htm.xml XML 4747
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 25761606
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)